Association of TYK2 (rs2304255) and DDX58 (rs34085293) gene variants with comorbidities in patients with severe psoriasis
Vestnik dermatologii i venerologii · 2026-10-08 · 102 (4) · 58-67
DOI: 10.25208/vdv17029 ↗Abstract
BACKGROUND: Severe psoriasis is strongly associated with metabolic syndrome; however, the genetic predictors determining susceptibility to comorbid conditions remain largely unexplored. AIM: To evaluate the association between TYK2 (rs2304255) and DDX58 (rs34085293) gene variants and comorbidities in patients with severe psoriasis. METHODS: This single-center, cross-sectional, observational study represents a secondary analysis of a cohort originally established to assess netakimab pharmacogenetics (70 patients: 45 men, 25 women; median age: 45 years). Comorbidities (dyslipidemia, hypertension, type 2 diabetes, hyperuricemia, and metabolic dysfunction-associated fatty liver disease) were cross-sectionally evaluated at screening, prior to initiating netakimab therapy. TYK2 (rs2304255) and DDX58 (rs34085293) genotyping was conducted by polymerase chain reaction. Associations were evaluated using Fisher exact test, the phi coefficient, and odds ratios (ORs), with the Benjamini–Hochberg procedure applied to adjust for multiple testing. RESULTS: Following adjustment for multiple comparisons, neither TYK2 nor DDX58 polymorphisms showed statistically significant associations with comorbidities. Noted trends for TYK2 C/C (OR = 4.67 in dyslipidemia) and DDX58 T/T (OR = 0.306 in dyslipidemia; OR = 0.405 in metabolic dysfunction-associated fatty liver disease) exhibited wide 95% confidence intervals spanning unity and non-significant adjusted p-values (0.287 and 0.501, respectively). No significant associations were observed for diabetes, hyperuricemia, or hypertension. CONCLUSION: Taken together, our data provide insufficient evidence to establish the studied TYK2 and DDX58 variants as definitive genetic determinants of the evaluated comorbidities. Nonetheless, the identified trends necessitate further investigation to generate and test new hypotheses.
EUVIMED